MedTrace Logo

Role of Tumoral Biomarker B3 Adrenergic Receptor in Paediatric Solid Tumours

NCT06312150 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2024-03-18

No results posted yet for this study

Summary

Childhood cancers are the third leading cause of death among children between the ages of 1 and 4, and the second leading cause of death among children aged 5-14 years. Biologically, it has been demonstrated that tumour aggressiveness and invasive capacity are caused by genetic modifications and cellular microenvironmental factors in a sequential and multifactorial process. The search for genetic alterations, proteins, or entire intracellular signalling pathways involved in the process of carcinogenesis and metastatisation is always evolving in order to identify new prognostic factors or potential therapeutic targets. In recent years, β-adrenergic receptors (β-ARs) have been associated with tumour progression.

This is a multicentre biological samples study which main aim is to evaluate the β3 receptor expression in the peripheral blood of patients with solid tumours compared to a healthy control group. The biological samples collected during the study are: peripheral blood sample, bone marrow aspirate and fresh or fresh paraffin biopsy tumour.

Conditions

  • Tumor

Interventions

OTHER

Analysis of peripheral blood (control group)

Peripheral blood sample will be acquired in excess to the last scheduled control sample according to clinical practice.

OTHER

Analysis of biological sample (Substudy-solid neoplasms)

peripheral blood sample, bone marrow aspirate and fresh or paraffin biopsia tissutale will be collected for the substudy

OTHER

Analysis of biological sample (substudy-leukaemia patients)

sample of peripheral blood and bone marrow blood for the substudy, derived from paediatric or young adult leukaemia patients

Sponsors & Collaborators

  • Meyer Children's Hospital IRCCS

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
1 Day
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-12-17
Primary Completion
2025-09-30
Completion
2025-12-31

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06312150 on ClinicalTrials.gov